CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 276 enrolled
Drug / intervention
Escitalopram +1 moredrug
Likely dose
Escitalopram 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03522844
NCT03522844Phase 4Completed

Comparative Effectiveness of Mindfulness-Based Stress Reduction and Pharmacotherapy for Anxiety

Georgetown University·interventional·Posted May 11, 2018·Updated Jan 11, 2022

In Brief

A Phase 4 clinical trial evaluating Mindfulness-Based Stress Reduction and Escitalopram for Anxiety Disorders and 4 related conditions. Completed, enrolled 276 participants across 3 sites.

Detailed Summary

We propose the first randomized, controlled study to assess the comparative effectiveness of Mindfulness-Based Stress Reduction (MBSR) with a medication for anxiety disorders. We will use escitalopram, gold-standard SSRI treatment for patients with anxiety disorders, and will examine the comparative effectiveness of the two treatments on anxiety symptoms and other outcomes important to patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 4CompletedFinished
20192020202120222023202420252026
First PostedMay 11, 2018
Enrollment StartJun 18, 2018
Primary CompletionOct 31, 2021
Study CompletionJan 5, 2022
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 8.1 years ago

Interventions

Mindfulness-Based Stress Reductionother

Participants randomized to the MBSR intervention will consist of an 8-week Mindfulness-Based Stress Reduction (MBSR) program, taught and facilitated by a trained instructor. The classes instruct participants in the theory and practice of several forms of mindfulness meditation: a body scan, breathing awareness, and mindfulness stretching exercises designed to bring awareness of the body and current experience of movement. The intervention will include a weekly class for 8 weeks and classes will be 2.5 hours in duration. The intervention will also include a 1-day (7 hours) retreat on a weekend at the end of the program. Participants will also be asked to engage in 45 minutes of practice at home on a daily basis, as well as informal practice assignments that instruct participants to bring mindfulness to current daily activities.

Escitalopramdrug

Escitalopram is an antidepressant, widely used to treat anxiety disorders. During the 8 weeks of randomized treatment with escitalopram, subjects will be seen regularly by a study physician. The pill medication will be initiated at 10 mg/day; at week 2, dosage will be increased to 20 mg/day if well tolerated (or delayed if not). Side effects will be assessed at each visit and recorded.